Patent application number | Description | Published |
20080257349 | Multilevel Ventilator - A method and apparatus for detecting breathing disorders and controlling a breathing ventilator using an artificial neural network working on signals indicative of a patient's physiological status. Preferably the artificial neural network works on a signal indicative of the pressure or flow of supplied breathing gas divided into two or more intervals ( | 10-23-2008 |
20080261931 | Method and Means of Preventing and Treating Sleep Disordered Breathing - A method of treating or preventing snoring, obstructive sleep apnea (OSA) and/or central sleep apnea (CSA) comprises administering a pharmacologically effective amount a salt of acetylhomotaurine (AcHT) such as calcium acamprosate (CA) to a patient. Also disclosed is the use of AcHT and CA for the manufacture of a medicament for treating or preventing snoring, OSA and/or CSA and of a diagnostic device, kit or composition; a protective patch comprising AcHT or CA; and a pharmaceutical composition comprising AcHT or CA and an agent capable of alleviating the effects of snoring OSA and/or CSA, in combined amounts effective in the treatment of snoring OSA and/or CSA, and a carrier. | 10-23-2008 |
20080269278 | Treatment of Impaired Respiratory Function with Gaboxadol - The present invention relates to a method for treating impaired respiratory function in a human patient suffering from sleep apnea, such as central sleep apnea or obstructive sleep apnea, comprising administering to said patient an effective amount of gaboxadol per day. | 10-30-2008 |
20090304816 | METHOD AND COMPOSITION FOR TREATING AND DIAGNOSING RESTLESS LEGS SYNDROME - A method of treating Restless Legs Syndrome (RLS) comprises the joint administration of an agent selected from dopamine turnover increasing agent and dopaminergic receptor exciting agent, in particular pramipexole, and iron in a biologically usable form, in pharmacologically effective combined amounts. Also disclosed is a corresponding use; a pharmaceutical composition comprising an agent selected from dopamine turnover increasing agent and dopaminergic receptor exciting agent, in particular pramipexole, and iron in a biologically usable form, and a pharmaceutically acceptable carrier; a package comprising a pharmaceutical composition for per-oral administration comprising an agent selected from dopamine turnover increasing agent and dopaminergic receptor exciting agent and a pharmaceutically acceptable carrier and a pharmaceutical composition for per-oral administration comprising iron in a biologically usable form and a pharmaceutical acceptable carrier. | 12-10-2009 |
20100093787 | TREATMENT OF IMPAIRED RESPIRATORY FUNCTION WITH GABOXADOL - The present invention relates to a method for treating impaired respiratory function in a human patient suffering from sleep apnea, such as central sleep apnea or obstructive sleep apnea, comprising administering to said patient an effective amount of gaboxadol per day. | 04-15-2010 |
Patent application number | Description | Published |
20080249164 | Antimicrobial and Antinflammatory Composition - The invention relates to the use of at least davanone and 1,8-cineol for the manufacture of an antimicrobial and/or antiinflammatory composition as well as a method of producing said composition. | 10-09-2008 |
20090035375 | Pharmaceutical compositions for acute glucocorticoid therapy - The present invention relates to glucocorticoid-containing pharmaceutical compositions or kits for use in acute emergency situations where acute glucocorticoid therapy is required. Notably, the invention relates to pharmaceutical compositions and kits that are designed to be administered by non-medically trained persons outside a hospital or another medical or clinical setting. The invention also relates to a method for treating a disorder requiring acute glucocorticoid therapy by providing a fast onset of action of a glucocorticoid | 02-05-2009 |
20090221716 | Composition Comprising At Least 3 Different Diols - The present invention relates to a composition comprising at least 3 different diols, wherein said diols have the general structure (CH | 09-03-2009 |
20090232761 | Use of a Composition Comprising Pentane-1, 5-Diol as Deodorant - In one embodiment of the present invention, the use of a composition is disclosed including pentane-1,5-diol to reduce and/or eliminate odour from a mammal, such as odour from such as urine, faeces, liquids from leg ulcers, decubital ulcers, blood and perspiration. One embodiment of the present invention also relates to absorbent and/or sanitary products comprising pentane-1,5-diol. | 09-17-2009 |
20100062981 | USE OF FIBRINOGEN AS A PROPHYLACTIC TREATMENT TO PREVENT BLEEDING DURING AND AFTER SURGERY AND AS A BIOMARKER TO IDENTIFY PATIENT WITH AN INCREASED RISK FOR EXCESSIVE BLEEDING AND BLOOD TRANSFUSION - The present invention provides a method for preventing peri- and postoperative bleeding in subjects undergoing surgery, in particular subjects with a preoperative fibrinogen plasma level equal to or above the normal range. The method comprises administration of a substance with fibrinogen-like activity to the subject in an amount that result in a circulating fibrinogen plasma level of from about 1.0 g/L. The present invention also provides a method for determining the risk of subjects with a preoperative fibrinogen plasma level equal to or above the normal range to bleed postoperatively. Furthermore, the present invention provides means for predicting the necessity of blood or plasma transfusion after a subject with a preoperative fibrinogen plasma level equal to or above the normal range has been subject to a surgical procedure. The means involves measurement of the fibrinogen level of the subject before surgery and comparing the level with a risk curve. | 03-11-2010 |
20100331401 | ANTIMICROBIAL AND ANTIINFLAMMATORY COMPOSITION - The invention relates to the use of at least davanone and 1,8-cineol for the manufacture of an antimicrobial and/or antiinflammatory composition as well as a method of producing said composition. | 12-30-2010 |
20110020265 | USE OF OLIGOMERS OF LACTIC ACID IN THE TREATMENT OF GYNAECOLOGICAL DISORDERS - Use of the one or more oligomers of lactic acid with the following formula (I) wherein n is an integer from 2 to 25 such as, e.g., from 2 to 20, from 3 to 25, from 3 to 20, from 2 to 15, from 3 to 15, from 2 to 10, from 3 to 10, from 4 to 10, or from 4 to 9 or a lactic acid oligomeric product for the prophylaxis and/or treatment of a disease or condition that benefit of an acidic environment especially a gynaecological infection such as a bacterial infection, such as bacterial vaginosis, unspecific colpitis, senile colpitis, cervicitis, and urethritis, a fungal infection, such as candidosis ( | 01-27-2011 |
20120183610 | GLUCOCORTICOID THERAPY - The present invention relates to improved glucocorticoid therapy and to treatment or prevention of a number of disorders that are due to a diminished or disrupted endogenous glucocorticoid secretory pattern. The invention is based on the findings that producing a specific serum Cortisol time profile that mimics the circadian rhythm of Cortisol of a healthy subject in a subject suffering from a diminished or disrupted glucocorticoid secretory pattern gives benefits with respect to reduction of side-effects. | 07-19-2012 |
20130129823 | PHARMACEUTICAL COMPOSITIONS FOR GLUCOCORTICOID REPLACEMENT THERAPY - The invention relates to glucocorticoid replacement therapy and provides pharmaceutical compositions and kits designed to deliver one or more glucocorticoids to a subject in need thereon in a manner that results in serum levels of the glucocorticoid that essentially mimic that of a healthy subject for a clinically relevant period of time. The pharmaceutical compositions and kits are prepared in such a way that a first part of one or more glucocorticoids is substantially immediately released and a second part of one or more glucocorticoids is released over an extended period of time of at least about 8 hours. The invention also relates to a method for treating diseases requiring glucocorticoid treatment such as in subjects having a glucocorticoid deficiency disorder. | 05-23-2013 |
20130209565 | POSOLOGY AND ADMINISTRATION OF GLUCOCORTICOID BASED COMPOSITIONS - The present invention relates to an improved method of administration of glucocorticoid based compositions in glucocorticoid replacement therapies enabling an objectively based regimen for administration enabling correct individual dosing of glucocorticoids resulting in an optimised individual replacement therapy and thus an improved long-term outcome for patients with temporary or chronic adrenal insufficiency. | 08-15-2013 |
20130245112 | ANTIMICROBIAL AND ANTIINFLAMMATORY COMPOSITION - The invention relates to the use of at least davanone and 1,8-cineol for the manufacture of an antimicrobial and/or antiinflammatory composition as well as a method of producing said composition. | 09-19-2013 |
20140242167 | PHARMACEUTICAL COMPOSITIONS FOR GLUCOCORTICOID REPLACEMENT THERAPY - The invention relates to glucocorticoid replacement therapy and provides pharmaceutical compositions and kits designed to deliver one or more glucocorticoids to a subject in need thereon in a manner that results in serum levels of the glucocorticoid that essentially mimic that of a healthy subject for a clinically relevant period of time. The pharmaceutical compositions and kits are prepared in such a way that a first part of one or more glucocorticoids is substantially immediately released and a second part of one or more glucocorticoids is released over an extended period of time of at least about 8 hours. The invention also relates to a method for treating diseases requiring glucocorticoid treatment such as in subjects having a glucocorticoid deficiency disorder. | 08-28-2014 |
20150209375 | POSOLOGY AND ADMINISTRATION OF GLUCOCORTICOID BASED COMPOSITIONS - The present invention relates to an improved method of administration of glucocorticoid based composition in glucocorticoid replacement therapies enabling an objectively based regimen for administration enabling correct individual dosing of glucocorticoids resulting in an optimized individual replacement therapy and thus an improved long-term outcome for patients with temporary or chronic adrenal insufficiency. | 07-30-2015 |
Patent application number | Description | Published |
20130317104 | USE OF OLIGOMERS OF LACTIC ACID IN THE TREATMENT OF GYNAECOLOGICAL DISORDERS - The invention relates to the use of one or more oligomers of lactic acid or a lactic acid oligomeric product for the prophylaxis and/or treatment of a disease or condition that benefits from an acidic environment, especially a gynaecological infection including a bacterial infection such as bacterial vaginosis, unspecific colpitis, senile colpitis, cervicitis, and urethritis, a fungal infection, such as candidosis ( | 11-28-2013 |
20150025142 | USE OF OLIGOMERS OF LACTIC ACID IN THE TREATMENT OF GYNAECOLOGICAL DISORDERS - The invention relates to the use of one or more oligomers of lactic acid or a lactic acid oligomeric product for the prophylaxis and/or treatment of a disease or condition that benefits from an acidic environment, especially a gynaecological infection including a bacterial infection such as bacterial vaginosis, unspecific colpitis, senile colpitis, cervicitis, and urethritis, a fungal infection, such as candidosis ( | 01-22-2015 |